We are going to discuss accelerating advances in science, data and technology are opening up unprecedented opportunities to save lives, prevent disease and redesign care pathways, placing university hospitals at the centre of care, research and innovation. They are expected to translate this progress into world‑class outcomes for patients and to tackle persistent challenges – from late diagnoses and fragmented care to workforce pressure and unsustainable costs – while turning research excellence into better everyday care and strengthening national competitiveness.

In this closing panel, invited by the CEO of Sahlgrenska University Hospital, senior leaders from government, academia, healthcare and industry will explore what it takes to build and run a university hospital that is globally attractive for patients, clinicians, researchers and partners in life sciences. The discussion will be explicitly action‑oriented, aiming to turn shared insights into concrete next steps for every actor on and off the stage.

A key focus will be the Swedish national life science strategy and its impact on university hospitals – from clinical research and precision health to digital infrastructure and data‑driven innovation. How can hospitals translate strategic ambitions into everyday priorities in wards, labs and boardrooms, and which critical decisions need to be made in the coming years?

Another central theme is how to design public–private partnerships that create real value for patients and society. Leading university hospitals depend on technology providers, medtech and pharma to innovate, while these companies rely on high‑quality clinical environments and health data to develop safe, relevant solutions. How do we organise collaboration so that it solves real problems in care and research – not just pilots that never scale – and which practical principles should guide that work?

The panel will also address the ethical and legal frameworks needed for trustworthy collaboration: from access to and use of health data, to fair benefit‑sharing, transparency and clear limits for commercial use. Where should we draw the boundaries, and how do we maintain public trust when data, AI and advanced therapies are core drivers of progress?

By the end of the session, each role – government, hospital management, clinicians, academia, tech and pharma – is expected to leave with a short, clear action list: what to start, what to stop and what to scale to help university hospitals lead in life sciences in the coming decade.